Common filaggrin gene mutations and risk of cervical cancer
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Common filaggrin gene mutations and risk of cervical cancer. / Bager, Peter; Wohlfahrt, Jan; Sørensen, Erik; Ullum, Henrik; Høgdall, Claus Kim; Palle, Connie; Husemoen, Lise Lotte Nystrup; Linneberg, Allan; Kjaer, Susanne K; Melbye, Mads; Thyssen, Jacob P.
I: Acta Oncologica, Bind 54, Nr. 2, 2015, s. 217-23.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Common filaggrin gene mutations and risk of cervical cancer
AU - Bager, Peter
AU - Wohlfahrt, Jan
AU - Sørensen, Erik
AU - Ullum, Henrik
AU - Høgdall, Claus Kim
AU - Palle, Connie
AU - Husemoen, Lise Lotte Nystrup
AU - Linneberg, Allan
AU - Kjaer, Susanne K
AU - Melbye, Mads
AU - Thyssen, Jacob P
PY - 2015
Y1 - 2015
N2 - BACKGROUND: As carriers of filaggrin gene (FLG) mutations may have a compromised cervical mucosal barrier against human papillomavirus infection, our primary objective was to study their risk of cervical cancer.METHODS: We genotyped 586 cervical cancer patients for the two most common FLG mutations, R501X and 2282del4, using blood from the Copenhagen Hospital Biobank, Denmark. Controls (n = 8050) were genotyped in previous population-based studies. Information on cervical cancer, mortality and emigration were obtained from national registers. Odds ratios (OR) were estimated by logistic regression with adjustment for age at blood sampling, and weighted by the genotype-specific inverse probability of death between diagnosis and sampling. Hazard ratios (HR) were estimated by Cox regression with time since diagnosis as underlying time, and with adjustment for age at diagnosis and stratification by cancer stage.RESULTS: The primary results showed that FLG mutations were not associated with the risk of cervical cancer (6.3% of cases and 7.7% of controls were carriers; OR adjusted 0.81, 95% CI 0.57-1.14; OR adjusted+ weighted 0.96, 95% CI 0.58-1.57). Among cases, FLG mutations increased mortality due to cervical cancer (HR 4.55, 95% CI 1.70-12.2), however, the association was reduced after stratification by cancer stage (HR 2.53, 95% CI 0.84-7.59).CONCLUSION: Carriage of FLG mutations was not associated with the risk of cervical cancer.
AB - BACKGROUND: As carriers of filaggrin gene (FLG) mutations may have a compromised cervical mucosal barrier against human papillomavirus infection, our primary objective was to study their risk of cervical cancer.METHODS: We genotyped 586 cervical cancer patients for the two most common FLG mutations, R501X and 2282del4, using blood from the Copenhagen Hospital Biobank, Denmark. Controls (n = 8050) were genotyped in previous population-based studies. Information on cervical cancer, mortality and emigration were obtained from national registers. Odds ratios (OR) were estimated by logistic regression with adjustment for age at blood sampling, and weighted by the genotype-specific inverse probability of death between diagnosis and sampling. Hazard ratios (HR) were estimated by Cox regression with time since diagnosis as underlying time, and with adjustment for age at diagnosis and stratification by cancer stage.RESULTS: The primary results showed that FLG mutations were not associated with the risk of cervical cancer (6.3% of cases and 7.7% of controls were carriers; OR adjusted 0.81, 95% CI 0.57-1.14; OR adjusted+ weighted 0.96, 95% CI 0.58-1.57). Among cases, FLG mutations increased mortality due to cervical cancer (HR 4.55, 95% CI 1.70-12.2), however, the association was reduced after stratification by cancer stage (HR 2.53, 95% CI 0.84-7.59).CONCLUSION: Carriage of FLG mutations was not associated with the risk of cervical cancer.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Case-Control Studies
KW - Denmark
KW - Female
KW - Heterozygote
KW - Humans
KW - Intermediate Filament Proteins
KW - Middle Aged
KW - Mutation
KW - Odds Ratio
KW - Regression Analysis
KW - Risk
KW - Uterine Cervical Neoplasms
U2 - 10.3109/0284186X.2014.973613
DO - 10.3109/0284186X.2014.973613
M3 - Journal article
C2 - 25383447
VL - 54
SP - 217
EP - 223
JO - Acta Oncologica
JF - Acta Oncologica
SN - 1100-1704
IS - 2
ER -
ID: 160797918